J Res Clin Med, 2024, 12: 14 doi: 10.34172/jrcm.32240 https://jrcm.tbzmed.ac.ir

Systematic Review





Effectiveness of transcutaneous electrical nerve stimulation (TENS) modality for treating myofascial pain syndrome: A systematic review and meta-analysis

Vahideh Toopchizadeh¹⁰, Behzad Izadseresht¹, Bina Eftekharsadat¹⁰, Hanieh Salehi-Pourmehr^{2*0}, Sanam Dolati^{1*0}

¹Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran

²Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran

Article info

Article History: Received: April 10, 2022 Accepted: November 30, 2022 ePublished: June 16, 2024

Keywords: Myofascial pain syndro

Myofascial pain syndrome, Pain management, TENS

Abstract

Introduction: Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder that initiates from myofascial trigger points (MTrPs) in skeletal muscle. This study aimed to systematically review the studies on the efficiency of transcutaneous electrical nerve stimulation (TENS) on MPS.

Methods: The data from PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials from the database inception to July 2021 were used. Two reviewers screened the papers independently, and took out the data based on the PRISMA protocol. Information associated with the study was gathered, including glocation, time, author, modality, details of comparisons between groups, duration of treatment, participants' characteristics, and duration of follow-up.

Results: Among 422 articles, a total of 21 articles met the exclusion and inclusion criteria for the study (including 12 trials) and 7 for meta-analysis. The overall estimated effect showed a significant decrease in Visual analog scale (VAS) score in the TENS group compared with the exercise group (MD=-1.60, 95% CI: -2.16 to -1.05, P<0.00001). However, there was no significant decrease in pain pressure threshold (PPT) score in the TENS group compared with sham (MD=1.88, 95% CI: -0.62 to 4.38, P=0.14) or exercise (MD=0.19, 95% CI: -0.79 to 1.37, P=0.75). TENS therapy did not improve the PPT score (MD=0.96, 95% CI: -0.72 to 2.64, P=0.26).

Conclusion: The published evidence for the treatment of MPS by TENS has been reviewed. TENS can be utilized as an adjuvant treatment to help alleviate MPS but should not be regarded as a monotherapy.

Introduction

Myofascial pain syndrome (MPS) is a type of chronic pain syndrome that appears in muscles, fascia, or related soft tissues and can be along with apparent emotional disorders or dysfunctions.¹ MPS is a regional pain disorder and a relapsing disease that affects every age group and is characterized by the presence of trigger points (TrPs) within muscles or fascia.² The predilection sites of MPS are the neck, shoulders, and back. About 30.0%-93.0% of the patients with musculoskeletal pain are exposed to MPS.³ Since there are many different treatment options accessible for MPS, treatment strategies should meet the lesion site, course of disease, and individual situation.⁴ At present, pharmacologic interventions consist of muscle relaxants such as benzodiazepines, tizanidine, and cyclobenzaprine; Tricyclic antidepressants (TCAs), and topical agents such as diclofenac gel and lidocaine patches, in addition to injection therapy of Botox or lidocaine are frequently used for pain relief in MPS. Other modalities including acupuncture, dry needling, and to a certain extent transcutaneous electrical nerve stimulation (TENS) therapy have been employed to help alleviate the chronic pain in MPS.⁵ TENS is the transcutaneous and noninvasive use of electrical stimulation to produce analgesia.⁶ It effectively improves pain in patients with MPS, and is theorized for increasing the release of endogenous opiates (enkephalins and β -endorphins), stimulating sensory nerves and gate-control mechanisms,

*Corresponding Authors: Hanieh Salehi-Pourmehr, Emails: salehiha@tbzmed.ac.ir, poormehrh@yahoo.com and Sanam Dolati, Emails: dolatis@tbzmed.ac.ir, sanam.dolati@gmail.com

^{© 2024} The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

modulating autonomic responses, and partly blocking C-fibers for pain relief.⁷ Conventional TENS applications were effective in pain relief and range of motion in patients with MPS.⁸

Systematically, we reviewed the information from randomized controlled trials (RCTs) and quasi-RCTs to assess of the efficiency of TENS modality in treating myofascial pain. Understanding the actual benefit of this modality is important clinically since it may help to develop good rehabilitation protocols for chronic MPS circumstances.

Methods

Study design

This systematic review was performed based on the predetermined guidelines presented by the Cochrane Collaboration (2008).⁹

Studies

All RCTs and quasi RCTs were included.

Participants

Inclusion criteria

All relevant studies involved patients with MPS, and sought treatment with the following modality: TENS.

Exclusion criteria

- Articles with no adequate patients (fewer than seven patients)
- All retrospective studies
- Studies with no access to full-text
- Withdrawn trials.

Interventions

TENS (transcutaneous electrical nerve stimulation).

Types of comparisons

The quantitative component of this review was considered placebo, sham controls, and other conventional controls including exercise.

Types of outcomes

Primarily, our objective was to assess the efficiency of TENS in pain relief. Visual analog scale (VAS) was included in valid reliable common scales for pain intensity evaluation and monitoring. The primary outcome was the efficacy of each modality using pain reduction according to the VAS questionnaire and pain pressure threshold (PPT) (using a Pressure Algometer).

Table 1 presents PICOS criteria for exclusion and inclusion of studies.

The strategy of article search

A systematic search was conducted in Cochrane Library, ProQuest, Clinicaltrial.gov, Web of Science, Google Scholar, Ovid, PubMed, and Scopus databases in July 2021. The studies were searched based on the keywords in line with the MeSH glossary. The review search ahead of published or printed articles was performed irrespective of time limitations or language. References accessible in review articles were assessed as further resources. Persian thesis was reviewed by searching the universities' websites. It also tried to search for articles available at conferences. However, no full access was found to the gray literature.

Data collection and analysis

Selecting the studies

The abstracts and titles of all studies recognized by the search approach were read independently by two authors. Once all potentially related articles were retrieved, the full text of each article was independently evaluated by each reviewer for inclusion and then methodological quality and acceptability of selected studies were assessed through the Cochrane appraisal risk of bias checklist. When there was not any consistency, the idea of the third author was considered and agreed upon.

Assessing the risk of bias

The articles were reviewed regarding selection detection, performance bias, reporting, and attrition bias. Also, an assessment was separately performed by two authors in terms of the Cochrane Handbook. The considered items included Random sequence generation (assessing for probable selection bias); allocation concealment (checking for potential selection bias); blinding of participants and personnel (assessing for possible performance bias); blinding of outcome assessment (checking for possible detection bias); selective reporting (checking for possible detection bias); and other bias.¹⁰ In all cases, a "low risk" assessment represented a low rate of bias, assessing "high risk" means a high rate of bias, and evaluating "unclear risk" represents the uncertain risk of bias.

 Table 1. PICOS criteria for inclusion and exclusion of studies

Parameter	
Participants	Patients with Myofascial pain syndrome
Intervention	Transcutaneous electrical nerve stimulation
Comparator	Placebo, sham or conventional methods including exercise.
Outcomes	Any beneficial effect on Pain reduction (using VAS questionnaire), and pain pressure threshold (using Pressure Algometer)
Study design	Randomized controlled trials (RCTs) or quasi-experimental studies.

2 | J Res Clin Med, 2024, 12: 14

Data extraction and management

Data were extracted using a form. Information associated with the study was gathered, including time, author, place, modality, comparison details between groups, treatment duration, follow-up duration, and participants' characteristics. The reports were summarized for studies published more than once, and those published with the most complete information were included in the study. These data were used for the results published only in older versions. All differences between the published versions must be considered. The information needed by the original author was requested via correspondence and the associated data was achieved. Disagreement was resolved through consultation with the third party, who is an expert in this field.

Data analysis

Owing to failure in quasi-experimental articles or complete report data, or a control arm rather than the placebo, sham, or conventional methods, meta-analysis was possible only on 16 articles.

Meta-analysis was performed through Review Manager 5.4.1 statistical software. The findings of the per-protocol analysis were utilized for meta-analysis for intention-to-treat analysis but the results were not reported. Here, all the results were quantitative. Moreover, mean and standard deviation were utilized for analysis before and after the intervention. Using standard deviation and mean changes in each group followed by the intervention in comparison with the baseline, and then, MD changes were calculated with a confidence interval of 95%. In this regard, mean changes from baseline was calculated by this formula:

Mean change = mean of follow-up measurement – mean of baseline measurement

To obtain standard deviation (SD) changes, the previously reported formula was used.¹¹

The quantity of heterogeneity amongst the included studies' results was assessed by the I² index indicating the variability percentage between studies. A value of more than 50% for this index, represents the higher heterogeneity. Finally, the meta-analysis was reported using a random effect. In addition, for heterogeneity less than 50%, the fixed-effect model was used for analysis. Through the forest plot, pooled results were presented, in case of at least two articles.

Results

Results of the search

In the first phase, 422 articles were collected from databases, and after eliminating the duplicated items, 365 articles remained. Then, the articles were assessed according to the inclusion criteria. Considering nonrelevance to this review, 340 were excluded based on the abstract and title. Ultimately, out of 25 articles, 21 were included in systematic review (including 12 trials),^{8,12-31} and seven of them for meta-analysis.^{8,12,13,15-18} (Figure 1).

Explanation of studies

All of the studies included in this systematic work published from 2002 to 2021, were clinical trials, and included a control group with a parallel arm or cross-over design. Of these, 17 were conducted in Turkey; the others were in India, Iran, South Korea, Taiwan, Thailand, USA, UK, Egypt, etc (Table 2).

Meta-analysis was performed only on seven articles^{8,12,13,15-18} (including 12 trials) owing to failure to completely report data or quasi-experimental articles, or a control arm rather than the placebo, sham, or conventional methods,

The outcome measurement tools were VAS, PPT, or both, and a minority of studies used a numeric pain rating scale, Nottingham Health Profile, or neck pain disability index to report their outcomes. Total sessions were varied between 1-30 as well as one to seven sessions per week. The included studies' modification was continuous, biphasic, or Burst/conventional. The frequency (MHz), effective radiating area (ERA) (cm²), Beam Nonuniformity Ratio (BNR), output (W/cm²), and duty cycle (%) are summarized in Tables 3 and 4.

Risk of bias in articles

Considering the Cochrane appraisal risk of bias checklist, all of the published articles included in the meta-analysis had moderate or good quality (Figures 2 and 3).

Effectiveness of TENS on pain relief

Fifteen RCTs used the TENS modality in one of the experimental or control arms, or either two different experiments alone in combination with other modalities such as electrical muscle stimulation (EMS), ischemic compression interferential therapy (IFT), or US.^{8,12-17,19,20,22,23,25-27,40}

Smania et al, in their study, compared the long, medium, and short-term impacts of peripheral repetitive magnetic stimulation (rMS) and TENS on 53 patients with MPS. Their results indicate that a long-lasting impact of rMS compared to the TENS.²⁸

In line with this result, Ardiç et al. compared the TENS and EMS on MPS on 40 patients in three different groups, including TENS+exercise, EMS+exercise, and only exercise. No statistical differences were found in any of the parameters between TENS and EMS groups at any time (P>0.05), indicating that there is no considerable superiority of the two electrotherapies methods on each other in long term evaluation, although the effectiveness of TENS is found immediately followed by treatment.⁸ Another RCT was performed by Sahin et al. on the effects of TENS and reported that TENS types were not greater than other MPS treatment groups or placebo.¹⁷



Figure 1. Search and selection process of systematic review

Author	Year	Type of study	Country	Modality	Control group modality	Case	Control	Mean age	Male	Female
Hou ¹⁵	2002	RCT	Taiwan	Group 1: ischemic compression ±TENS Group 2: exercise ±TENS	Exercise	Group 1: 9 Group 2: 9	21	46.89±14.91 and 51.00±16.19	8	31
Ardiç ⁸	2002	RCT	Turkey	Group 1: TENS Group 2: EMS	Exercise	Group 1:15 Group 2:15	10	41.73 ± 8.04 and 42.60 ± 9.40	4	36
Smania ²⁸	2005	RCT	Italy	TENS	Placebo	18	18	36.56±14.94 and 44.61±16.62	11	25
Gemmell ¹⁴	2010	Double-blind, randomized placebo- controlled trial	UK	TENS	Sham TENS	30	30	24.2-25.6	27	28
Sahin ¹⁷	2011	Randomized, placebo- controlled clinical trial	Turkey	Group 1: conventional TENS Group 2: conventional TENS Group 3: Burst TENS	Sham TENS	Group 1 :19 Group 2: 18 Group 3: 19	19	18-65	35	40
Rodríguez- Fernández ¹⁶	2011	Single blind randomized trial	Spain	TENS	Sham TENS	38	38	18-41	45	31
Ramanathan ¹⁹	2015	RCT	India	US and TENS	Exercise	15	15			
Azatcam ¹²	2016	Randomized, controlled, single- blind, prospective study	Turkey	TENS	Exercise	23	23	18-65	21	48
Kim ³²	2016	Single-blind RCT	Korea	US	Exercise (therapeutic inflatable ball)	18	22	67.71±5.65 and 71.15±5.06	5	40

 Table 2. Characteristics of the included studies

 Author
 Year

able 2. Continued.												
Author	Year	Type of study	Country	Modality	Control group modality	Case	Control	Mean age	Male	Female		
Dissanayake	2016	Single-blind RCT	Sir Lanka	Group 1: TENS Group 2: IFT	Hot pack, active range of motion exercises, myofascial release, and a home exercise program with postural advice	Group 1: 35 Group 2: 35	35	18-55	47	58		
Takla ¹⁸	2018	RCT	Egypt	G1: burst-TENS-CT: burst transcutaneous electrical nerve stimulation combined therapy, G2: AMF-CT	Sham TENS	Group 1:23 Group 2:25	22	34.39±5.92 and 34.88±5.67 and 35.18±5.56	30	40		
Jeon ³⁴	2012	RCT	Korea	ESWT	TPI+TENS	15	15	G1:40.86±13.07; G2:45.00+15.46	G1:13; G2:9	G1:2; G2:6		
Kim ²⁴	2014	RCT	Korea	G1: NSAID patch, G2: NSAID patch+TENS, G3: NSAID patch+heating pad, and G4: NSAID patch+topical capsaicin	G1:25; G2:24; G3:25; G4:25	-	-	G1:44.76±12.71; G2:49.17±13.52; G3:47.56±10.67; G4:48.88±11.11	-	-		
León- Hernández ²⁵	2014	RCT	Spain	Needling+TENS	Needling	31	31	26.81 ± 9.63; G2: 23.32 ± 4.77	G1:7; G2:9	G1:24; G2:22		
Chalkoo ²¹	2015	RCT	India	G1: conventional treatment including muscle relaxants, analgesics, soft diet, and hot fomentations; G2: TENS; G3: combined conventional and TENS treatment	Placebo	each 15	15	17-60	23	37		
Amjad 20	2016	RCT	Pakistan	TENS	US	32	32	G1:32±1; G2:37±9.9	25	39		
Rai ²⁷	2016	RCT	India	G1: TENS; G2:US	control	30;30	30	$\begin{array}{c} G1:29.73 \pm 8.804;\\ G2:32 \pm 10.174;\\ G3:34.93 \pm 12.57 \end{array}$	6;7;12	24;23;18		
Khalifeh 23	2018	RCT	Iran	G1: TENS + pharmacot G3: sham LLLT	therapy; G2: LLLT;	G1:18; G2:19	18	18-60				
Mansourian ²⁶	2018	RCT	Iran	TENS+medication	LLLT + medication; medication	36	36, 36	21-60	18.54%	81.46%		
Chiou 22	2019	RCT	Taiwan	TENS on the acupuncture point	TENS on trigger point	30	30	G1: 42.13 (12.93); G2: 41.98 (15.04)	G1: 25; G2: 23	G1: 5; G2:7		
Gezginaslan 31	2020	Prospective, randomized, single-blind clinical study	Turkey	ESWT	US, HP, TENS group	49	45	44.2±11.94	16	78		

AMF-CT, amplitude modulated frequency combined therapy; LLLT, low-level laser therapy; IFT, interferential therapy; TENS, transcutaneous electrical nerve stimulation; ESWT, extracorporeal shock wave therapy; US, Ultrasound; HP, hot pack; BNR, Beam Nonuniformity Ratio; ERA, effective radiating area; GP, Group

Ramanathan et al compared the impact of conventional physiotherapy (TENS and Ultrasound (US)) with ischemic compression using stretching in MPS treatment. They observed that ischemic pressure was more effective than the conventional method in reducing pain.¹⁹ Rodríguez-Fernández et al showed contrary results with the application of burst-type TENS for ten minutes and concluded a small but statistically significant increase in the PPT over upper trapezius latent myofascial trigger points (MTrPs).¹⁶

Hou et al, in their RCT on 119 subjects, assessed the immediate effects of physical therapeutic modalities on myofascial pain in the upper trapezius muscle and concluded that therapeutic combinations are most operative for MPS relief like TENS, hot pack plus active ROM and stretch with spray, hot pack plus an active range of motion (ROM) and stretch with spray, as well as, hot pack plus active ROM, interferential current and myofascial release technique.¹⁵

Gemmell et al compared the results of TENS and sham on 60 MPS patients and observed that TENS was superior to placebo in reducing pain but had no better effect than placebo in improving PPT.¹⁴

Azatcam et al, in an RCT on 69 MPS patients, compared the effect of TENS+exercise, Kinesio Taping (KT)+exercise, and exercise only on the pain, and revealed a reduction in pain in all groups immediately after treatment and three months after treatment (P<0.01). However, the VAS score was reduced in the KT group in comparison to the control group and TENS (P=0.001),

Table 3. Characteristics of the used modality

Author	Year	Modification	Frequency (MHz)	ERA (cm ²)	BNR	Output (W/cm ²)	Duty cycle%	Total session	Sessions per week
Hou ¹⁵	2002	Biphasic	-	-	-	-	-	14	7
Ardiç ⁸	2002	Biphasic	-	-	-	-	-	1	1
Smania ²⁸	2005	Biphasic	-	-	-	-	-	10	5
Gemmell ¹⁴	2010		-	-	-	-	-	1	1
Sahin ¹⁷	2011	Burst/ conventional	-	-	-	-	-		
Rodríguez- Fernández ¹⁶	2011	Burst	-	-	-	-	-	1	1
Ramanathan 19	2015	Pulse/burst	1			1.5		30	5
Azatcam ¹²	2016	Biphasic						10	5
Kim ³²	2016	Continuous	1	40		1	100	8	2
Dissanayake ³³	2016	Biphasic						8	2
Takla ¹⁸	2018	Group 1: Burst TENS Group 2: AMF TENS	-	-	-	-	-	12	3
Jeon ³⁴	2012		-	-	-	-	-		
Kim ²⁴	2014		-	-	-	-	-	2	2
León-Hernández ²⁵	2014	Conventional	2	-	-	-	-	3	2
Chalkoo ²¹	2015	Conventional	10 Htz	-	-	-	-	3	3-day interval
Amjad ²⁰	2016	Conventional- continuous	1	-	-	1.5	-	12	
Rai ²⁷	2016	Conventional	-	-		0.73	-	12	3 times every 2 weeks
Khalifeh 23	2018	-	-	-		200 mW/cm ²	-	10	two times a week
Mansourian ²⁶	2018	-	-	-		-	-	10	3
Chiou ²²	2019	-	0.6/60 Hz	-	-	-	-	7	Seven consecutive days
Gezginaslan ³¹	2020	-	-	-	-	1.5	-	7	Three days interval

AMF, amplitude modulated frequency; TENS, transcutaneous electrical nerve stimulation; ESWT, extracorporeal shock wave therapy; US, Ultrasound; HP, hot pack; BNR, Beam Nonuniformity Ratio; ERA, effective radiating area

and in the TENS group compared to the control group (P=0.011) after treatment. Considering the evaluations after 3 months and, the VAS score was reduced in the TENS group in comparison to the control group (P=0.001), as well as in the KT group than the control group (P=0.001). No considerable differences were found between KT and TENS groups.¹² In line with the influential role of TENS in pain reduction, Dissanayaka showed that TENS with standard care facilitates had better outcomes than IFT.13 Takla investigated the effect of combination therapy with the application of US and TENS. In their trial, 70 patients underwent the burst-TENS-combined therapy (CT), medium-frequency, low-intensity amplitude modulated frequency (AMF)-CT, or sham-CT control groups. Both combination therapies effectively increased PPT.¹⁸ Other trials reported a better efficacy of TENS in combination with other modalities, including needling,²⁵ or pharmacotherapies (methocarbamol and naproxen)²³ (fluoxetine, clonazepam, baclofen)26 in comparison to needling,²⁵ or low-level laser (LLL) approaches. However, in comparison the TENS,^{20,27} the efficacy of US significantly was higher. In addition, TENS on the acupuncture point was accompanied by superior improvement than the TENS on the TrP in pain intensity.²²

Our meta-analysis included only the studies in which

TENS was used only in the intervention arm and compared them with sham, placebo, or exercise. The only combination therapy included in our meta-analysis belonged to the combination therapy of TENS and exercise in the experimental group.¹⁵

Results of Meta-analysis

Effectiveness of TENS on VAS score

Five RCTs, including seven trials with 214 participants who evaluated the efficacy of TENS compared to placebo or control, sham or exercise, were eligible to be included in the meta-analysis.^{8,12,13,15,17} The scale used was VAS. However, one of them had a combination of standard care for the control arm (active ROM exercises, myofascial release, hot pack, and a home exercise program with postural advice), which was not considered in this meta-analysis.13 The I2 index represented considerable heterogeneity between studies ($I^2 = 88\%$, *P* value < 0.0001); thus, a random effect model was utilized to pool the data. A significant reduction was found by the overall estimated effect in VAS score in the TENS group in comparison to the exercise group (MD=-1.60, 95% CI: -2.16 to -1.05, P < 0.001). Sahin et al, had three intervention groups: Group 1 received a conventional TENS with a frequency of 100 Hz, 40 µs duration, low amplitude; Group 2 with an Table 4. The outcomes measure tools and results

		Interventio	n group	Control group				
Author	VAS (pre)	VAS (post)	PPT (pre)	PPT (post)	VAS (pre)	VAS (post)	PPT (pre)	PPT (post)
Hou ¹⁵	Group 1: 4.69±2.24 Group 2: 4.68±1.28	Group 1: 2.46±1.33 Group 2: 2.43±0.65	Group 1: 2.68±0.75 Group 2: 3.09±1.10	Group 1: 3.39±0.83 Group 2: 3.93±1.03	5.10±1.78	4.33±1.82	3.07±0.96	3.45±1.09
Ardiç ⁸	Group 1: 7.40±1.88 Group 2: 7.00±1.20	Group 1: 4.27±2.28 Group 2: 4.13±2.59	Group 1: 2.00±0.76 Group 2: 2.00±0.85	Group 1: 0.80±0.68 Group 2: 1.07±0.59	7.50 ± 1.84	6.50±2.55	2.10±0.74	1.70 ± 0.95
Smania ²⁸	Range: 40-50	Range:30-40			Range:40-50	Range:40-50		
Gemmell ¹⁴			4.0 ± 1.4	3.51			4.0 ± 1.4	3.55
Sahin ¹⁷	Group 1:7.12 ± 1.87 Group 2:6.15 ± 1.18 Group 3:6.85 ± 1.35	Group 1: 6.85±1.55 Group 2: 6.55±1.42 Group 3: 6.10±2.15			7.56±1.17	6.95±1.15		
Rodríguez- Fernández ¹⁶			2.1 ± 0.5	2.7 ± 0.7			2.2 ± 0.8	2.2 ± 0.8
Ramanathan ¹⁹	7.06 ± 0.798	5.93 ± 0.703			7.13 ± 0.833	3.60 ± 0.828		
Azatcam ¹²	7.39 ± 0.66	1.78 ± 0.74	16.75 ± 2.34	24.12 ± 3.02	7.21 ± 0.51	2.95 ± 0.97	16.75 ± 1.94	22.82 ± 3.39
Kim ³²	5.31 ± 1.52	2.67 ± 1.82	2.07 ± 0.70	2.45 ± 0.87	6.15 ± 1.62	3.34 ± 1.95	1.92 ± 0.34	2.50 ± 0.04
Dissanayake ³³	Group 1:69.9±2.8 Group 2:67.2±8.7	Group 1: 45.3±8.4 Group 2: 31.8±6.2			70.3 ± 4.2	17.6±3.1		
Takla ¹⁸			Group 1: 0.27±0.18 Group 2: 0.75±0.16	Group 1: 4.57±0.57 Group 2 :2.73±0.35			0.71±0.16	1.86±0.17
Jeon ³⁴	6.86 ± 0.90	1.86 ± 0.69	6.86 ± 1.35	12.57 ± 0.72	7.20 ± 1.30	2.80 ± 0.84	6.20 ± 1.92	9.60 ± 2.19
Kim ²⁴			$\begin{array}{c} G1:\ 2.47\pm 0.83;\\ G2:\ 2.79\pm 1.41;\\ G3:\ 2.67\pm 0.74;\\ G4:\ 2.59\pm 0.89 \end{array}$		$\begin{array}{c} G1:2.42 \pm 1.00;\\ G2:2.94 \pm 1.12;\\ G3:3.01 \pm 0.82;\\ G4:2.89 \pm 0.83 \end{array}$			
León- Hernández ²⁵	4.82 ± 1.83	2.00 (1.00 and 5.00)	1.80 ± 0.90	1.70 (1.18 and 6.75)	4.82 ± 1.91	2.50 (1.00 and 4.00)	1.72 ± 0.81	1.50 (1.15 and 1.87)
Chalkoo ²¹	G1: 3.7 (1.05); G2:4.0 (1.07); G3: 5.0 (1.31)	G1: 0.6 (0.91); G2: 1.4 (0.91); G3: 0.1 (0.35)			4.1 (0.64)	4.1 (0.83)		
Amjad 20	6 times a week for two weeks.							
Rai ²⁷	240.60 ± 25.75	32.37 ± 13.02			247.87 ± 26.53	20.87 ± 6.35		
Khalifeh ²³	Trapezius: G1: 1.926±1.777; G2: 2±1.763	G1: 1.515±0.812; G2: 1.444±1.423			1.833 ± 2.526	2.666±2.894		
Mansourian ²⁶	4.13 ± 1.75	4.77 ± 0.27			G1 :4.09±1.76; G2: 2.87±0.98	G1: 4.90± 5.01±	0.27; G2: 0.27	
Chiou ²²	6.70 (1.18)	2.93 (1.64)			6.20 (1.35)	3.10 (1.42)		
Gezginaslan ³¹	8.3 ± 1.2	3.7 ± 1.7			8.1 ± 1.3	6.5 ± 1.2		

acupuncture-like TENS with a frequency of 4 Hz, 250 μ s duration, high amplitude; Group 3 with burst TENS with high [100 Hz] and low [2 Hz] frequency, 40 μ s, and high amplitude. A control group was treated with electrical stimulation until the patient felt it. The results of subgroup analysis with the control arm of sham TENS showed no statistical difference between the groups (MD: 0.45, 95% CI: -0.21 to 1.12, *P*=0.18). Also, test for the overall effect of TENS compared to the control arm (either sham or exercise) did not show any significant difference between

study groups (MD = -0.67, 95% CI: -1.70 to 0.36, P = 0.20). Our results also showed that TENS therapy did not ameliorate patients' pain using the VAS scale (Figure 2).

Effectiveness of TENS on PPT score

Five RCTs involving 222 participants who evaluated the efficacy of TENS compared to placebo or control or sham or exercise were included in the meta-analysis.^{8,12,15,16,18,35} The scale used was PPT. The I² index showed significant heterogeneity between studies (I²=99%, P<0.00001), and

TENS Control Mean Difference									Mean D)ifference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rand	om, 95% Cl	ABCDEFG
1.1.1 exercise											
Ardic.F 2002	-3.13	2.11	15	-1	2.28	10	12.5%	-2.13 [-3.90, -0.36]		-	? 🗧 ? ? 🖶 ? 🖶
Azatcam.G 2016	-5.61	0.7	23	-4.26	0.78	23	19.3%	-1.35 [-1.78, -0.92]	•	el i i i i i i i i i i i i i i i i i i i	• ? • • • ? •
D.Dissanayaka.T 2016	-24.6	7.41	35	-35.4	7.76	35	0.0%	10.80 [7.25, 14.35]			?? 🔴 🔴 🤋 🤁
Huo.C-R 2002	-2.25	1.11	9	-0.07	1.8	21	16.5%	-2.18 [-3.24, -1.12]			?????+?+
Sahin.N (1) 2011	-0.27	1.73	19	-0.61	1.16	19		Not estimable			? • • • • ? •
Sahin.N (2) 2011	0.4	1.32	18	-0.61	1.16	19		Not estimable			?
Sahin.N (3) 2011	-0.75	1.88	19	-0.61	1.16	19		Not estimable			? • • • • ? •
Subtotal (95% CI)			47			54	48.3%	-1.60 [-2.16, -1.05]	•		
Heterogeneity: Tau ² = 0.07	r; Chi⁼=	: 2.55,	df = 2 ((P = 0.28	3); I² =	21%					
Test for overall effect: Z = 5	5.68 (P	< 0.00	001)								
1.1.2 sham											
Sahin.N (1) 2011	-0.27	1.73	19	-0.61	1.16	19	17.1%	0.34 [-0.60, 1.28]		+	?
Sahin.N (2) 2011	0.4	1.32	18	-0.61	1.16	19	17.8%	1.01 [0.21, 1.81]		-	?
Sahin.N (3) 2011	-0.75	1.88	19	-0.61	1.16	19	16.8%	-0.14 [-1.13, 0.85]		+	?
Subtotal (95% CI)			56			57	51.7%	0.45 [-0.21, 1.12]		*	
Heterogeneity: Tau ² = 0.13	3; Chi ^z =	3.26,	df = 2 (P = 0.20	0); I ² =	39%					
Test for overall effect: Z = 1	1.34 (P	= 0.18)								
Total (95% CI)			103			111	100.0%	-0.67 [-1.70, 0.36]	•	•	
Heterogeneity: Tau ² = 1.38	3; Chi ⁼ =	: 41.97	', df = 5	(P < 0.0	00001)	; I ² = 88	3%		-10 -5		_
Test for overall effect: $Z = 1$	1.28 (P	= 0.20)						TENS	Control	
Test for subgroup differen	ces: Ch	ni² = 21	.64, df	= 1 (P <	0.000	01), l ² =	= 95.4%		TENC		

Risk of bias legend

(A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)
 (E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias



TENS Control Mean Difference Mean Differ									Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
2.1.1 exercise										
Ardic.F 2002	-1.19	0.72	15	-0.4	0.86	10	20.5%	-0.79 [-1.44, -0.14]		? 🛑 ? ? 🖶 ? 🖶
Azatcam.G 2016	7.37	2.74	23	6.07	2.95	23	17.5%	1.30 [-0.35, 2.95]	+	•?•••
Huo.C-R 2002	0.9	1.07	9	0.38	1.03	21	20.1%	0.52 [-0.31, 1.35]	+	?????+?+
L.Rodriguez-F.A 2011	0.6	0.6	38	0	0.8	38		Not estimable		??
N Takla. M. K 2018	4.3	0.5	23	1.15	0.17	22		Not estimable		
N Takla. M K 2018	1.98	0.3	25	1.15	0.17	22	0.0%	0.83 [0.69, 0.97]		
Subtotal (95% CI)			47			54	58.1%	0.19 [-0.99, 1.37]	•	
Heterogeneity: Tau ² = 0.	81; Chi²	= 9.28	8, df = 2	(P = 0.0	010); P	'= 78%				
Test for overall effect: Z =	= 0.32 (F	P = 0.7	5)							
2.1.2 sham										
L Rodriguez-E A 2011	0.6	0.6	38	0	0.8	38	20.9%	0.60 (0.28, 0.92)	•	??
N Takla, M, K 2018	4.3	0.5	23	1.15	0.17	22	21.0%	3 15 [2 93, 3 37]		
Subtotal (95% CI)	110	0.0	61		0.11	60	41.9%	1.88 [-0.62, 4.38]		
Heterogeneity: Tau ² = 3.	23: Chi ^a	= 168	.90. df :	= 1 (P <	0.000	01); I ² =	99%		_	
Test for overall effect: Z =	= 1.47 (F	P = 0.1	4)			.,,,,				
Total (95% CI)			108			114	100.0%	0.96 [-0.72, 2.64]		
Heterogeneity: Tau ² = 3	49 [.] Chi ²	= 267	50 df:	= 4 (P <	0 000	01): I ² =	99%			
Test for overall effect: 7:	= 1 1 2 /	P = 0.2	.30, un• 6)	40.4	0.000		33.0		-4 -2 0 2 4	
Test for subgroup differe	ences (:hi ² = 1	43 df	= 1 (P =	0.23	$I^{2} = 30$	2%		TENS Control	
Risk of higs legend	JII000. 0		.40, 01	(0.20)	, - 50	. 2 .0			
(A) Random sequence (iteranan	on (co	laction	hiae)						
(A) Random Sequence i	generau	011 (36	ie calon	0103)						

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 3. Forest plot of comparison TENS vs. control on PPT score

therefore a random effect model was used to pool the data. The overall estimated effect showed no significant decrease in PPT score in the TENS group compared with sham (MD=1.88, 95% CI: -0.62 to 4.38, P=0.14) or exercise (MD=0.19, 95% CI: -0.99 to 1.37, P=0.75). In total, TENS therapy did not improve the PPT score (MD = 0.96, 95% CI: -0.72 to 2.64, P = 0.26) (Figure 3).

Discussion

MPS is poorly understood and remains a challenging condition to treat. Effective management of MPS is to diagnose it early, subsequently intensive, protocol-based,

multi-disciplinary rehabilitation applying a combination of medication, rest, physiotherapy, and effective use of various trigger point management techniques. Myofascial pain is typically treated by interventions directed at modifying trigger point sensitivity.³⁶ The primary objective of treatment is to resolve the pathologic conditions of MPS. Reducing the disability and pain are the secondary treatment objectives.³⁷ TENS is efficient, safe, and a relatively simple physical modality usually utilized in painful conditions. The TENS devices lead to patients less dependence to analgesics and narcotics.38 The present work reviewed all available evidence from RCTs and quasi RCTs systematically to summarize the effects of TENS on pain scores in myofascial pain. The use of the TENS in the management of MPS has been wellestablished, previously. In this regard, a study conducted by Wessberg et al, reported a much higher rate of pain reduction (95%) in patients with myofascial pain.³⁹ Kruger et al in 1998 determined that in treating chronic pain, the application of TENS has been proposed as a practical adjunct modality.⁴⁰ Additionally, it has been reported that 63.6% of patients with myalgia were completely relieved of pain after receiving TENS therapy, while another study reported that 23.3% of patients were pain-free following TENS.41,42

To date, data about the comparison of different TENS protocols in the tr0eatment of MPS are limited.^{17,18} On the other hand, the studies regarding the efficacy of TENS in the treatment of MPS are conflicting.^{7,16,17} Moreover, a recent systematic review also found that TENS is effective for the treatment of MPS.⁴³ As stated by the present study, TENS is superior to placebo in pain reduction and pain perception improvement. TENS can decrease pain severity and increase pain threshold in MPS patients, as well.

According to the clinical studies using TENS at various frequencies, moderate to high TENS frequencies (20-80 Hz), are most effective to reduce pain intensity regarding high frequencies i.e.,100 Hz or low frequencies <10 Hz in both clinical and healthy subjects.⁴⁴ The findings also showed primary evidence that treatment sessions with durations higher than 15 min have more effectiveness compared to the short-duration sessions.⁴³

In general, TENS was beneficial among the noninvasive therapeutic modalities.³⁷ The difference in pain reduction in the mentioned studies is ascribed to the difference between the samples with regard to variations in biological and social constituents affecting the MPS, along with the stimulation parameters used in the TENS therapy.

Study limitations

Several limitations are present in this study. Only seven studies were included in the meta-analysis. However, all of the included studies were RCTs, and we performed a quality assessment of the risk of bias to overcome this limitation. All studies included in this analysis possessed a relatively small sample size. It must be highlighted that the duration of therapeutic effect and effect sizes are often limited; therefore, real clinical impact should be determined with further large-scaled clinical research.

Conclusion

This manuscript reviewed the main aspects of TENS on pain scores in myofascial pain. Thus, TENS can be utilized as an adjuvant treatment to help alleviate MPS but should not be regarded as a monotherapy. The results of trials were heterogeneous because of large variability within the applied parameters and protocols. The limited sample size and poor quality of these studies highlight and support the need for additional studies with larger numbers of participants, and good quality placebo-controlled trials in this area.

Acknowledgments

The authors would like to thank the Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran, and the Evidencebased Medical Research Center, Tabriz University of Medical Sciences, Tabriz, Iran for supporting this work.

Authors' Contribution

Conceptualization: Vahideh Toopchizadeh. Data curation: Bina Eftekharsadat. Formal analysis: Hanieh Salehi-Pourmehr. Funding acquisition: Vahideh Toopchizadeh; Bina Eftekharsadat. Investigation: Hanieh Salehi-Pourmehr, Sanam Dolati, Behzad Isadseresht. Methodology: Hanieh Salehi-Pourmehr. Project administration: Sanam Dolati. **Resources:** Hanieh Salehi-Pourmehr. Software: Hanieh Salehi-Pourmehr. Supervision: Vahideh Toopchizadeh, Bina Eftekharsadat, Sanam Dolati. Validation: Vahideh Toopchizadeh; Bina Eftekharsadat. Visualization: Vahideh Toopchizadeh; Bina Eftekharsadat. Writing-original draft: Sanam Dolati; Behzad Isadseresht. Writing-review & editing: Vahideh Toopchizadeh, Bina Eftekharsadat, Sanam Dolati, Hanieh Salehi-Pourmehr.

Competing Interests

There is no conflict of interest.

Ethical Approval

The current study was approved by the Research Ethics Committee of the Tabriz University of Medical Science (No: IR.TBZMED. REC.1400.926).

Funding

Not applicable.

References

- Saxena A, Chansoria M, Tomar G, Kumar A. Myofascial pain syndrome: an overview. J Pain Palliat Care Pharmacother. 2015;29(1):16-21. doi: 10.3109/15360288.2014.997853.
- Urits I, Charipova K, Gress K, Schaaf AL, Gupta S, Kiernan HC, et al. Treatment and management of myofascial pain syndrome. Best Pract Res Clin Anaesthesiol. 2020;34(3):427-48. doi: 10.1016/j.bpa.2020.08.003.
- 3. Fredy DM, Harpin D, Mihardja H. The role of acupuncture

for myofascial pain syndrome (MPS) in interventional pain management. J Complement Integr Med. 2022;19(2):213-217. doi: 10.1515/jcim-2021-0525.

- Cao QW, Peng BG, Wang L, Huang YQ, Jia DL, Jiang H, et al. Expert consensus on the diagnosis and treatment of myofascial pain syndrome. World J Clin Cases. 2021;9(9):2077-89. doi: 10.12998/wjcc.v9.i9.2077.
- Galasso A, Urits I, An D, Nguyen D, Borchart M, Yazdi C, et al. A comprehensive review of the treatment and management of myofascial pain syndrome. Curr Pain Headache Rep. 2020;24(8):43. doi: 10.1007/s11916-020-00877-5.
- Martimbianco ALC, Porfírio GJ, Pacheco RL, Torloni MR, Riera R. Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain. Cochrane Database Syst Rev. 2019;12(12):CD011927. doi: 10.1002/14651858.CD011927. pub2.
- 7. Vance CG, Dailey DL, Rakel BA, Sluka KA. Using TENS for pain control: the state of the evidence. Pain Manag. 2014 May;4(3):197-209. doi: 10.2217/pmt.14.13.
- Ardiç F, Sarhus M, Topuz O. Comparison of two different techniques of electrotherapy on myofascial pain. J Back Musculoskelet Rehabil. 2002;16(1):11-6. doi: 10.3233/bmr-2002-16103.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142. doi: 10.1002/14651858.ed000142.
- Fu R, Vandermeer BW, Shamliyan TA, O'Neil ME, Yazdi F, Fox SH, et al. AHRQ methods for effective health care. Handling continuous outcomes in quantitative synthesis. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality (US); 2008.
- 12. Azatcam G, Atalay NS, Akkaya N, Sahin F, Aksoy S, Zincir O, et al. Comparison of effectiveness of Transcutaneous Electrical Nerve Stimulation and Kinesio Taping added to exercises in patients with myofascial pain syndrome. J Back Musculoskelet Rehabil. 2017;30(2):291-8. doi: 10.3233/bmr-150503.
- Dissanayaka TD, Pallegama RW, Suraweera HJ, Johnson MI, Kariyawasam AP. Comparison of the effectiveness of transcutaneous electrical nerve stimulation and interferential therapy on the upper trapezius in myofascial pain syndrome: a randomized controlled study. Am J Phys Med Rehabil. 2016;95(9):663-72. doi: 10.1097/phm.000000000000461.
- Gemmell H, Hilland A. Immediate effect of electric point stimulation (TENS) in treating latent upper trapezius trigger points: a double blind randomised placebo-controlled trial. J Bodyw Mov Ther. 2011;15(3):348-54. doi: 10.1016/j. jbmt.2010.04.003.
- Hou CR, Tsai LC, Cheng KF, Chung KC, Hong CZ. Immediate effects of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity. Arch Phys Med Rehabil. 2002;83(10):1406-14. doi: 10.1053/ apmr.2002.34834.
- Rodríguez-Fernández AL, Garrido-Santofimia V, Güeita-Rodríguez J, Fernández-de-Las-Peñas C. Effects of burst-type transcutaneous electrical nerve stimulation on cervical range of motion and latent myofascial trigger point pain sensitivity. Arch Phys Med Rehabil. 2011;92(9):1353-8. doi: 10.1016/j. apmr.2011.04.010.
- 17. Sahin N, Albayrak I, Ugurlu H. Effect of different transcutaneous

electrical stimulation modalities on cervical myofascial pain syndrome. J Musculoskelet Pain. 2011;19(1):18-23. doi: 10.3109/10582452.2010.538825.

- Takla MK. Low-frequency high-intensity versus mediumfrequency low-intensity combined therapy in the management of active myofascial trigger points: a randomized controlled trial. Physiother Res Int. 2018;23(4):e1737. doi: 10.1002/ pri.1737.
- Ramanathan K, Nathan CS, Kumar GM, Rajavel R. Effect of conventional physiotherapy [tens and ultrasound] vs ischemic compression with stretching in the treatment of active myofascial trigger points for upper back. J Physiother Occup Ther. 2015;1(2):7-13.
- Amjad F, Shahid HA, Batool S, Ahmad A, Ahmed I. A comparison on efficacy of transcutaneous electrical nerve stimulation and therapeutic ultrasound in treatment of myofascial trigger points. Khyber Med Univ J. 2016;8(1):3-6.
- 21. Chalkoo AH, Nazir N. Evaluation of conventional therapy, transcutaneous electric nerve stimulation therapy, and placebo in management of myofascial pain-dysfunction syndrome: a comparative study. J Adv Clin Res Insights. 2016;3(2):51-5. doi: 10.15713/ins.jcri.105.
- 22. Chiou YF, Yeh ML, Wang YJ. Transcutaneous electrical nerve stimulation on acupuncture points improves myofascial pain, moods, and sleep quality. Rehabil Nurs. 2020;45(4):225-33. doi: 10.1097/rnj.00000000000198.
- Khalifeh S, Rezaee E, Azizi A, Ebrahimi H. Efficacy of lowlevel laser versus transcutaneous electrical nerve stimulation for treatment of myofascial pain syndrome: a clinical trial. J Res Dent Maxillofac Sci. 2018;3(3):33-41. doi: 10.29252/ jrdms.3.3.33.
- 24. Kim DH, Yoon KB, Park S, Jin TE, An YJ, Schepis EA, et al. Comparison of NSAID patch given as monotherapy and NSAID patch in combination with transcutaneous electric nerve stimulation, a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome of the upper trapezius: a pilot study. Pain Med. 2014;15(12):2128-38. doi: 10.1111/pme.12611.
- León-Hernández JV, Martín-Pintado-Zugasti A, Frutos LG, Alguacil-Diego IM, de la Llave-Rincón AI, Fernandez-Carnero J. Immediate and short-term effects of the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronic myofascial neck pain. Braz J Phys Ther. 2016;20(5):422-31. doi: 10.1590/bjpt-rbf.2014.0176.
- Mansourian A, Pourshahidi S, Sadrzadeh-Afshar MS, Ebrahimi H. A comparative study of low-level laser therapy and transcutaneous electrical nerve stimulation as an adjunct to pharmaceutical therapy for myofascial pain dysfunction syndrome: a randomized clinical trial. Front Dent. 2019;16(4):256-64. doi: 10.18502/fid.v16i4.2084.
- Rai S, Ranjan V, Misra D, Panjwani S. Management of myofascial pain by therapeutic ultrasound and transcutaneous electrical nerve stimulation: a comparative study. Eur J Dent. 2016;10(1):46-53. doi: 10.4103/1305-7456.175680.
- Smania N, Corato E, Fiaschi A, Pietropoli P, Aglioti SM, Tinazzi M. Repetitive magnetic stimulation: a novel therapeutic approach for myofascial pain syndrome. J Neurol. 2005;252(3):307-14. doi: 10.1007/s00415-005-0642-1.
- 29. Jeon JH, Jung YJ, Lee JY, Choi JS, Mun JH, Park WY, et al. The effect of extracorporeal shock wave therapy on myofascial pain syndrome. Ann Rehabil Med. 2012;36(5):665-74. doi: 10.5535/arm.2012.36.5.665.
- Kim M, Lee M, Kim Y, Oh S, Lee D, Yoon B. Myofascial pain syndrome in the elderly and self-exercise: a single-blind, randomized, controlled trial. J Altern Complement Med. 2016;22(3):244-51. doi: 10.1089/acm.2015.0205.
- 31. Gezgİnaslan Ö, Gümüş Atalay S. High-energy flux density

extracorporeal shock wave therapy versus traditional physical therapy modalities in myofascial pain syndrome: a randomized-controlled, single-blind trial. Arch Rheumatol. 2020;35(1):78-89. doi: 10.5606/ArchRheumatol.2020.7496.

- 32. Kim M, Lee M, Kim Y, Oh S, Lee D, Yoon B. Myofascial pain syndrome in the elderly and self-exercise: a single-blind, randomized, controlled trial. J Altern Complement Med. 2016;22(3):244-51. doi: 10.1089/acm.2015.0205.
- 33. Dissanayake TD, Kariyawasam A, Pallegama RW, Suraweera HJ, Dassanayake T. Immediate Effectiveness of Transcutaneoue Electrical Nerve Stimulation (Tens) in Treating Trigger Points of the Upper Trapezius in Myofascial Pain Syndrome: A Preliminary Study. Sri Lanka: University of Peradeniya; 2013.
- 34. Jeon JH, Jung YJ, Lee JY, Choi JS, Mun JH, Park WY, et al. The effect of extracorporeal shock wave therapy on myofascial pain syndrome. Ann Rehabil Med. 2012;36(5):665-74. doi: 10.5535/arm.2012.36.5.665.
- Takla MK, Rezk-Allah SS. Immediate effects of simultaneous application of transcutaneous electrical nerve stimulation and ultrasound phonophoresis on active myofascial trigger points: a randomized controlled trial. Am J Phys Med Rehabil. 2018;97(5):332-8. doi: 10.1097/phm.00000000000876.
- Gerwin RD. Diagnosis of myofascial pain syndrome. Phys Med Rehabil Clin. 2014;25(2):341-55. doi: 10.1016/j. pmr.2014.01.011.
- Desai MJ, Bean MC, Heckman TW, Jayaseelan D, Moats N, Nava A. Treatment of myofascial pain. Pain Manag. 2013;3(1):67-79. doi: 10.2217/pmt.12.78.
- Vasudev S, Vakade CD, Paramesh RC, Govind BP. Transcutaneous electric nerve stimulation: an adjuvant

modality for pain relief in myofascial pain dysfunction syndrome. J Med Radiol Pathol Surg. 2017;4(4):9-11.

- Wessberg GA, Carroll WL, Dinham R, Wolford LM. Transcutaneous electrical stimulation as an adjunct in the management of myofascial pain-dysfunction syndrome. J Prosthet Dent. 1981;45(3):307-14. doi: 10.1016/0022-3913(81)90396-6.
- Kruger LR, van der Linden WJ, Cleaton-Jones PE. Transcutaneous electrical nerve stimulation in the treatment of myofascial pain dysfunction. S Afr J Surg. 1998;36(1):35-8.
- 41. Patil S, Iyengar AR, Kotni RM, B VS, Joshi RK. Evaluation of efficacy of ultrasonography in the assessment of transcutaneous electrical nerve stimulation in subjects with myositis and myofascial pain. Korean J Pain. 2016;29(1):12-7. doi: 10.3344/kjp.2016.29.1.12.
- Moger G, Shashikanth MC, Sunil MK, Shambulingappa P. Transcutaneous electrical nerve stimulation therapy in temporomandibular disorder: a clinical study. J Indian Acad Oral Med Radiol. 2011;23(1):46-50. doi: 10.5005/jpjournals-10011-1090.
- 43. Ahmed S, Haddad C, Subramaniam S, Khattab S, Kumbhare D. The effect of electric stimulation techniques on pain and tenderness at the myofascial trigger point: a systematic review. Pain Med. 2019;20(9):1774-88. doi: 10.1093/pm/pny278.
- Johnson MI, Ashton CH, Bousfield DR, Thompson JW. Analgesic effects of different frequencies of transcutaneous electrical nerve stimulation on cold-induced pain in normal subjects. Pain. 1989;39(2):231-6. doi: 10.1016/0304-3959(89)90010-9.